Table 2 Mean (S.D.) Platelet Contractile Force, Clot Elastic Modulus and Thrombin Generation Time at Baseline and Following Increasing Enoxaparin Antifactor Xa Activity
From: A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease
| Â | Group I | Group II | Group III | Â |
|---|---|---|---|---|
Antifactor Xa Activity | Controls (n = 10) | Renal Dysfunction (n = 13) | Diabetes and Renal Dysfunction (n = 7) | P-value |
Baseline | Â | Â | Â | Â |
PCF†| 8.5 (1.4) | 9.8 (1.5) | 12.0 (2.9)* | 0.003 |
CEM‡ | 23.2 (5.4) | 29.0 (9.5) | 37.3 (15.5)* | 0.03 |
TGT§ | 222.0 (60.3) | 235.4 (53.2) | 270.0 (52.0) | NS |
0.25 IU/mL | Â | Â | Â | Â |
PCF | 7.0 (1.8) | 7.5 (1.6) | 8.8 (2.9) | NS |
CEM | 21.1 (4.1) | 22.6 (4.1) | 24.6 (7.1) | NS |
TGT | 273.0 (68.5) | 327.7 (70.8) | 325.7 (76.3) | NS |
0.50 IU/mL | Â | Â | Â | Â |
PCF | 5.5 (1.9) | 5.6 (1.8) | 6.3 (2.4) | NS |
CEM | 17.2 (5.1) | 19.1 (4.4) | 19.4 (5.0) | NS |
TGT | 318.0 (68.1) | 440.0 (97.5)* | 420.0 (86.6) | 0.007 |
1.0 IU/mL | Â | Â | Â | Â |
PCF | 3.6 (1.7) | 3.0 (1.7) | 4.0 (2.1) | NS |
CEM | 11.9 (4.5) | 10.0 (4.6) | 12.9 (6.1) | NS |
TGT | 423.0 (128.4) | 588.5 (96.0)* | 552.9 (114.7) | 0.005 |
3.0 IU/mL | Â | Â | Â | Â |
PCF | 1.5 (1.3) | 0.6 (0.2) | 1.0 (0.9) | 0.06 |
CEM | 4.8 (4.4)* | 0.8 (0.8) | 0.9 (0.8) | 0.003 |
TGT | 780.0 (317.5) | 1200.0 (0)* | 1200.0 (0)* | < 0.0001 |